Page last updated: 2024-11-06

6-methylthiopurine and Bowel Diseases, Inflammatory

6-methylthiopurine has been researched along with Bowel Diseases, Inflammatory in 46 studies

6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.

Research Excerpts

ExcerptRelevanceReference
" We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD."5.48Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. ( Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018)
"Recent studies in patients with inflammatory bowel diseases (IBD) on thiopurine therapy suggest that too low 6-thioguanine nucleotide concentrations (6-TGN) and too high methylmercaptopurine nucleotide concentrations (MMPN) can be reversed by a combination therapy of allopurinol and low-dose thiopurines."5.17Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. ( Curkovic, I; Frei, P; Fried, M; Jetter, A; Kullak-Ublick, GA; Rentsch, KM; Rogler, G, 2013)
" Participants with optimal dosing in the morning had an earlier chronotype by corrected midpoint of sleep."3.30Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial. ( Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023)
"Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations."2.84Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. ( Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017)
"Pregnancy has a major effect on maternal thiopurine metabolism."2.79Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. ( de Boer, NK; de Jong, DJ; Dijkstra, G; Hommes, DW; Jharap, B; Mulder, CJ; Oldenburg, B; Stokkers, P; van Bodegraven, AA; van der Woude, CJ; van Elburg, RM, 2014)
" However, adverse events leading to discontinuation may occur in 10-20% of patients."2.716-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. ( de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003)
" However, because of their complex metabolism and potential toxicities, optimal use of biomarkers to predict adverse effects and therapeutic response is paramount."2.53Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. ( Loftus, EV; Moon, W, 2016)
" For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported."2.44Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007)
"Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies."1.62Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. ( Beukers, R; Bodelier, A; de Boer, N; de Lima, A; Depla, ACTM; Dijkstra, G; Erler, N; Escher, JC; Gilissen, L; Hoentjen, F; Jansen, JM; Kanis, SL; Kuyvenhoven, J; Mahmmod, N; Mallant-Hent, RC; Modderman, S; Noruzi, A; Oldenburg, B; Oostenbrug, LE; Pierik, M; Romberg-Camps, M; Ter Borg, PCJ; Thijs, W; van der Meulen-de Jong, AE; van der Woude, CJ; van Dijk, ARM; West, R, 2021)
" To assess if IFX influenced thiopurine metabolites, eight patients who had responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included."1.48A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. ( Ainsworth, MA; Brynskov, J; Mogensen, DV; Nersting, J; Schmiegelow, K; Steenholdt, C, 2018)
" Dosing history, concomitant therapy, and comorbidity data were assessed."1.48Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine. ( Barclay, ML; Mulder, CJ; Munnig-Schmidt, E; Zhang, M, 2018)
" We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD."1.48Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. ( Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018)
"Azathioprine dose was titrated on therapeutic efficacy (response and adverse effects)."1.46Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease. ( Aloi, M; Arrigo, S; Barabino, A; Cuzzoni, E; Decorti, G; Favretto, D; Franca, R; Knafelz, D; Martelossi, S; Martinelli, M; Miele, E; Naviglio, S; Romano, C; Stocco, G; Ventura, A, 2017)
"This study explored the relationship between the weight-based dosage of AZA and metabolites levels in 86 pediatric IBD patients using multilevel analysis."1.39Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis. ( Boulieu, R; Lachaux, A; Nguyen, TM; Nguyen, TV; Vu, DH, 2013)
" Prospective studies are needed to determine whether routine testing to guide dosing is of benefit."1.39Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. ( Andrews, JM; Asser, TL; Bampton, PA; Doogue, MP; Kennedy, NA; Mountifield, RE, 2013)
" The primary outcome was the occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology Criteria for Adverse Events."1.38Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. ( de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012)
" Measuring thiopurine metabolites is useful for dosage adjustment in children, and for the detection of potential toxicity."1.37Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. ( Armstrong, L; Bishop, J; Galloway, P; McGrogan, P; Russell, RK; Sharif, JA, 2011)
"Azathioprine treatment is a long-term therapy and therefore it is at risk for non-adherence, which is considered an important determinant of treatment inefficacy."1.36Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. ( Bartoli, F; Campanozzi, A; Decorti, G; Londero, M; Malusa, N; Marino, S; Martelossi, S; Stocco, G; Ventura, A, 2010)
"Azathioprine (AZA) has a slow onset of action in treatment of pediatric inflammatory bowel disease (IBD)."1.36Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. ( Beránek, M; Chládek, J; Dědek, P; Hroch, M; Krásničanová, P; Malý, J; Pozler, O, 2010)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (30.43)29.6817
2010's30 (65.22)24.3611
2020's2 (4.35)2.80

Authors

AuthorsStudies
Swanson, GR1
Biglin, M1
Raff, H1
Chouhan, V1
Jochum, S1
Shaikh, M1
Francey, L1
Bishehsari, F1
Hogenesch, J1
Keshavarzian, A1
Kanis, SL1
Modderman, S1
Escher, JC1
Erler, N1
Beukers, R1
de Boer, N1
Bodelier, A1
Depla, ACTM1
Dijkstra, G2
van Dijk, ARM1
Gilissen, L1
Hoentjen, F1
Jansen, JM1
Kuyvenhoven, J1
Mahmmod, N1
Mallant-Hent, RC1
van der Meulen-de Jong, AE1
Noruzi, A1
Oldenburg, B2
Oostenbrug, LE1
Ter Borg, PCJ1
Pierik, M1
Romberg-Camps, M1
Thijs, W1
West, R1
de Lima, A1
van der Woude, CJ2
Waljee, AK2
Sauder, K1
Patel, A1
Segar, S1
Liu, B1
Zhang, Y1
Zhu, J2
Stidham, RW1
Balis, U1
Higgins, PDR1
Mogensen, DV1
Brynskov, J1
Ainsworth, MA1
Nersting, J1
Schmiegelow, K2
Steenholdt, C1
Wall, GC1
Muktar, H1
Effken, C1
Mahajan, PB1
Munnig-Schmidt, E1
Zhang, M2
Mulder, CJ6
Barclay, ML5
Serpico, MR1
Maltz, R1
Crandall, W1
Bricker, J1
Dotson, JL1
Kim, SC1
Boyle, B1
Roberts, RL1
Wallace, MC1
Seinen, ML3
van Bodegraven, AA6
Krishnaprasad, K1
Jones, GT1
van Rij, AM1
Baird, A1
Lawrance, IC1
Prosser, R1
Bampton, P1
Grafton, R1
Simms, LA1
Studd, C1
Bell, SJ1
Kennedy, MA1
Halliwell, J1
Gearry, RB4
Radford-Smith, G1
Andrews, JM2
McHugh, PC1
Sánchez Rodríguez, E1
Ríos León, R1
Mesonero Gismero, F1
Albillos, A1
Lopez-Sanroman, A1
Takahashi, K1
Bamba, S1
Morita, Y1
Nishida, A1
Kawahara, M1
Inatomi, O1
Sugimoto, M1
Sasaki, M1
Andoh, A1
Jharap, B3
de Boer, NK4
Stokkers, P1
Hommes, DW1
de Jong, DJ3
van Elburg, RM1
Nguyen, TV2
Vu, DH1
Nguyen, TM2
Lachaux, A2
Boulieu, R3
Curkovic, I1
Rentsch, KM2
Frei, P1
Fried, M2
Rogler, G1
Kullak-Ublick, GA2
Jetter, A1
Blaker, PA1
Arenas-Hernandez, M1
Smith, MA1
Shobowale-Bakre, EA1
Fairbanks, L1
Irving, PM2
Sanderson, JD1
Marinaki, AM1
Moon, W1
Loftus, EV1
Wong, DR1
Coenen, MJ1
Derijks, LJ2
Vermeulen, SH1
van Marrewijk, CJ1
Klungel, OH1
Scheffer, H1
Franke, B1
Guchelaar, HJ1
Engels, LG2
Verbeek, AL1
Hooymans, PM2
Stocco, G2
Martelossi, S2
Arrigo, S1
Barabino, A1
Aloi, M1
Martinelli, M1
Miele, E1
Knafelz, D1
Romano, C1
Naviglio, S1
Favretto, D1
Cuzzoni, E1
Franca, R1
Decorti, G2
Ventura, A2
Alvarez Beltran, M1
Infante Pina, D1
Tormo Carnicé, R1
Segarra Cantón, O1
Redecillas Ferreiro, S1
Joyce, JC1
Wang, S1
Saxena, A1
Hart, M1
Higgins, PD1
de Graaf, P2
Vos, RM1
de Boer, NH1
Sinjewel, A1
Veldkamp, AI2
Vikingsson, S1
Carlsson, B1
Almer, S1
Peterson, C1
Haines, ML1
Ajlouni, Y1
Sparrow, MP1
Rose, R1
Gibson, PR1
Gerich, ME1
Quiros, JA1
Marcin, JP1
Tennyson, L1
Henthorn, M1
Prindiville, TP1
Londero, M1
Campanozzi, A1
Marino, S1
Malusa, N1
Bartoli, F1
Pozler, O1
Chládek, J1
Malý, J1
Hroch, M1
Dědek, P1
Beránek, M1
Krásničanová, P1
Roblin, X1
Oussalah, A1
Chevaux, JB1
Sparrow, M1
Peyrin-Biroulet, L1
Armstrong, L1
Sharif, JA1
Galloway, P1
McGrogan, P1
Bishop, J1
Russell, RK1
Smid, K1
van Asseldonk, DP2
Bouma, G1
Peters, GJ1
van Egmond, R1
Chin, P1
Sies, CW1
Shih, DQ1
Nguyen, M1
Zheng, L1
Ibanez, P1
Mei, L1
Kwan, LY1
Bradford, K1
Ting, C1
Targan, SR1
Vasiliauskas, EA1
Kennedy, NA1
Asser, TL1
Mountifield, RE1
Doogue, MP1
Bampton, PA1
Bloomfeld, RS1
Onken, JE1
Gilissen, LP1
Jansen, JB1
Wright, S1
Sanders, DS1
Lobo, AJ1
Lennard, L1
Goldenberg, BA1
Rawsthorne, P1
Bernstein, CN1
Hindorf, U1
Lyrenäs, E1
Nilsson, A1
Wusk, B1
Rammert, C1
von Eckardstein, A1
Dervieux, T1
Meyer, G1
Barham, R1
Matsutani, M1
Barry, M1
Neri, B1
Seidman, E1
Banerjee, S1
Bishop, WP1
Gardiner, SJ1
Begg, EJ1
Sau, A1
Marinaki, A1
Swaminath, A1
Kornbluth, A1
Pike, MG1
Franklin, CL1
Mays, DC1
Lipsky, JJ1
Lowry, PW1
Sandborn, WJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.[NCT00521950]853 participants (Actual)Interventional2007-09-30Completed
Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649]388 participants (Actual)Observational2002-03-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for 6-methylthiopurine and Bowel Diseases, Inflammatory

ArticleYear
Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Pharmacotherapy, 2018, Volume: 38, Issue:2

    Topics: Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Guanine Nucleotides; Humans; Immunosuppre

2018
Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:8

    Topics: Azathioprine; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Methyltransferases; Pharmacogenet

2016
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:8

    Topics: Antimetabolites, Antineoplastic; Azathioprine; Bone Marrow; Erythrocytes; Guanine Nucleotides; Human

2005
Optimizing drug therapy in inflammatory bowel disease.
    Current gastroenterology reports, 2007, Volume: 9, Issue:6

    Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal

2007

Trials

6 trials available for 6-methylthiopurine and Bowel Diseases, Inflammatory

ArticleYear
Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
    Clinical and translational gastroenterology, 2023, 02-01, Volume: 14, Issue:2

    Topics: Azathioprine; Chronotherapy; Cross-Over Studies; Humans; Inflammatory Bowel Diseases; Mercaptopurine

2023
Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Gut, 2014, Volume: 63, Issue:3

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anemia, Neonatal; Azathioprine; Biomarkers; Female;

2014
Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:8

    Topics: Adult; Aged; Allopurinol; Azathioprine; Female; Guanine Nucleotides; Humans; Inflammatory Bowel Dise

2013
Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Chemical and Drug Induced Liver Injury; Cohort Studies

2017
Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
    Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:12

    Topics: Adolescent; Adult; Allopurinol; Azathioprine; Child; Dose-Response Relationship, Drug; Drug Therapy,

2011
6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
    European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:1

    Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug

2003

Other Studies

36 other studies available for 6-methylthiopurine and Bowel Diseases, Inflammatory

ArticleYear
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut, 2021, Volume: 70, Issue:7

    Topics: Adalimumab; Adult; Anti-Bacterial Agents; Autoimmune Diseases; Cesarean Section; Child Development;

2021
Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.
    Journal of Crohn's & colitis, 2017, Jul-01, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Algorithms; Area Under Curve; Azathioprine; Drug Prescriptions; Female; Hospitali

2017
A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
    Journal of Crohn's & colitis, 2018, Feb-28, Volume: 12, Issue:3

    Topics: Adult; Antibodies; Drug Synergism; Drug Therapy, Combination; Erythrocytes; Female; Gastrointestinal

2018
Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
    Inflammatory bowel diseases, 2018, 03-19, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Female; Humans; Inflammatory Bowel Diseases; Male; Mer

2018
Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
    Journal of pediatric gastroenterology and nutrition, 2018, Volume: 67, Issue:3

    Topics: Adolescent; Adult; Allopurinol; Azathioprine; Child; Child, Preschool; Dose-Response Relationship, D

2018
Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease.
    Inflammatory bowel diseases, 2018, 11-29, Volume: 24, Issue:12

    Topics: Adult; Azathioprine; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Cohort Studies; Female

2018
Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
    Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:10

    Topics: Adult; Aged; Azathioprine; Biotransformation; Dose-Response Relationship, Drug; Drug Monitoring; Fem

2018
pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism.
    Digestion, 2019, Volume: 100, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal;

2019
Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:2

    Topics: Adolescent; Age Factors; Azathioprine; Child; Dose-Response Relationship, Drug; Female; Guanine Nucl

2013
Mechanism of allopurinol induced TPMT inhibition.
    Biochemical pharmacology, 2013, Aug-15, Volume: 86, Issue:4

    Topics: Adult; Allopurinol; Azathioprine; Case-Control Studies; Drug Therapy, Combination; Erythrocytes; Fem

2013
Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:9

    Topics: Adolescent; Antimetabolites; Azathioprine; Child; Child, Preschool; Drug Resistance; Female; Humans;

2013
Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease.
    Inflammatory bowel diseases, 2017, Volume: 23, Issue:4

    Topics: Adolescent; Age of Onset; Antimetabolites; Azathioprine; Case-Control Studies; Child; Child, Prescho

2017
[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].
    Anales de pediatria (Barcelona, Spain : 2003), 2009, Volume: 70, Issue:2

    Topics: Adolescent; Azathioprine; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Inflammat

2009
Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Artificial Intelligence; Child; Child, Presc

2010
Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010, Jun-01, Volume: 878, Issue:19

    Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Inflammatory Bowel Diseases; Mercaptop

2010
How should thiopurine treatment be monitored?--methodological aspects.
    Nucleosides, nucleotides & nucleic acids, 2010, Volume: 29, Issue:4-6

    Topics: Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mercaptopurine; Purines; Thioguanine

2010
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Inflammatory bowel diseases, 2011, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Azathioprine; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Cr

2011
A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Drug Administratio

2010
Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:5

    Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Guanine Nucleotides; Hepatitis, Autoimmun

2010
Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:6

    Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Genotype; Guanine Nucleotides; Humans; Im

2010
Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts.
    Inflammatory bowel diseases, 2011, Volume: 17, Issue:12

    Topics: Azathioprine; Biomarkers; Cross-Sectional Studies; Gastroenterology; Genetic Testing; Genotype; Glob

2011
Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Alimentary pharmacology & therapeutics, 2011, Volume: 34, Issue:9

    Topics: Adolescent; Azathioprine; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response Relationsh

2011
Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    Journal of Crohn's & colitis, 2012, Volume: 6, Issue:1

    Topics: Antimetabolites, Antineoplastic; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Human

2012
High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:10

    Topics: Antimetabolites, Antineoplastic; Azathioprine; Chromatography, High Pressure Liquid; Drug Resistance

2012
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
    Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Azathioprine; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; Imm

2012
Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.
    Internal medicine journal, 2013, Volume: 43, Issue:3

    Topics: Adult; Biomarkers; Disease Management; Female; Guanine Nucleotides; Humans; Inflammatory Bowel Disea

2013
Mercaptopurine metabolite results in clinical gastroenterology practice.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:1

    Topics: Azathioprine; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Patient Compliance; Risk Factors;

2003
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
    Gut, 2004, Volume: 53, Issue:8

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Azathioprine; Child;

2004
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
    The American journal of gastroenterology, 2004, Volume: 99, Issue:9

    Topics: Adult; Azathioprine; Biomarkers; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Dose-Response R

2004
Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Scandinavian journal of gastroenterology, 2004, Volume: 39, Issue:11

    Topics: Adolescent; Adult; Azathioprine; Drug Monitoring; Erythrocytes; Female; Genotype; Guanine Nucleotide

2004
Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:12

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cohort Studi

2004
Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Clinical chemistry, 2005, Volume: 51, Issue:11

    Topics: Adult; Azathioprine; Chromatography, Liquid; Cohort Studies; Drug Therapy, Combination; Erythrocytes

2005
Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
    Journal of pediatric gastroenterology and nutrition, 2006, Volume: 43, Issue:3

    Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Erythr

2006
Thiopurine treatment in inflammatory bowel disease.
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:9

    Topics: Adult; Antimetabolites; Breast Feeding; Dose-Response Relationship, Drug; Female; Humans; Infant; In

2007
Stability of thiopurine metabolites: a potential analytical bias.
    Clinical chemistry, 2008, Volume: 54, Issue:1

    Topics: Bias; Guanine Nucleotides; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Prospective Studies;

2008
Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Jun-05, Volume: 757, Issue:1

    Topics: Chromatography, High Pressure Liquid; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Reproduci

2001